Nuclear factor high‐mobility group box1 mediating the activation of toll‐like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Hepatology

• Publication date

  2011-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/hep.24552PMID 21809356
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease

  2011cited by this paper
• You deserve what you eat: lessons learned from the study of the melanin-concentrating hormone (MCH)-deficient mice

  2010cited by this paper
• Toll-like receptor-2 deficiency enhances non-alcoholic steatohepatitis

  2010cited by this paper
• Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice.

  2010cited by this paper
• Kupffer cell activation is a causal factor for hepatic insulin resistance.

  2010cited by this paper
• HMGB1 loves company

  2009cited by this paper
• Toll-like receptors as targets in chronic liver diseases

  2009cited by this paper
• Toll-like receptors and cancer

  2009cited by this paper
• Depletion of Liver Kupffer Cells Prevents the Development of Diet-Induced Hepatic Steatosis and Insulin Resistance

  2009cited by this paper
• Liver NF‐κB and AP‐1 DNA Binding in Obese Patients

  2009cited by this paper
• Toll‐like receptor 4 is involved in the development of fructose‐induced hepatic steatosis in mice

  2009cited by this paper
• Critical role of Kupffer cells in the management of diet-induced diabetes and obesity.

  2009cited by this paper
• The lysosomal‐mitochondrial axis in free fatty acid–induced hepatic lipotoxicity

  2008cited by this paper
• Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis.

  2007influential reference
• TLR4 enhances TGF-beta signaling and hepatic fibrosis.

  2007cited by this paper
• TLR4 activation mediates kidney ischemia/reperfusion injury.

  2007cited by this paper
• From fat to inflammation.

  2006cited by this paper
• TLR4 links innate immunity and fatty acid-induced insulin resistance.

  2006cited by this paper
• IKK-beta links inflammation to obesity-induced insulin resistance.

  2005cited by this paper
• Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB

  2005cited by this paper
• NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis.

  2005cited by this paper
• IKK-β links inflammation to obesity-induced insulin resistance

  2005cited by this paper
• Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB.

  2005cited by this paper
• TLRs: Professor Mechnikov, sit on your hat.

  2004cited by this paper
• Involvement of Toll-like Receptors 2 and 4 in Cellular Activation by High Mobility Group Box 1 Protein*

  2004cited by this paper
• Free fatty acids promote hepatic lipotoxicity by stimulating TNF‐α expression via a lysosomal pathway

  2004cited by this paper
• Toll-like receptor signalling

  2004cited by this paper
• O0040 FREE FATTY ACIDS PROMOTE HEPATIC LIPOTOXICITY BY STIMULATING TNF‐ALPHA EXPRESSION VIA A LYSOSOMAL PATHWAY

  2004cited by this paper
• Toll-like receptor 4 involvement in hepatic ischemia/reperfusion injury in mice.

  2004cited by this paper
• Toll-like Receptor Signaling*

  2003cited by this paper
• Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses.

  2002cited by this paper
• Release of chromatin protein HMGB1 by necrotic cells triggers inflammation

  2002cited by this paper
• Toll‐like receptor 4 is involved in the mechanism of early alcohol‐induced liver injury in mice

  2001cited by this paper
• Steatohepatitis: a tale of two "hits"?

  1998cited by this paper
• A human homologue of the Drosophila Toll protein signals activation of adaptive immunity

  1997cited by this paper

• Toll Like Receptor 4: A Potential Link Between Obesity and Metabolic Diseases.

  2026cites this paper
• Targeted hepatic delivery of ezetimibe via red blood cell-coated nanoparticles for the treatment of non-alcoholic fatty liver disease through inflammation modulation.

  2025cites this paper
• DC-SIGN+ macrophages alleviate metabolic dysfunction-associated steatotic liver disease via fine-tuning TLR4 signaling and inflammatory secretory profiles.

  2025cites this paper
• Cadmium exposure during adolescence and young adulthood induces signatures of metabolic dysfunction-associated steatotic liver disease

  2025cites this paper
• C-C motif chemokines ligand 7 contributes to metabolic dysfunction-associated steatotic liver disease by enabling redox-sensitive induction of hypermethylated in cancer 1.

  2025cites this paper
• Longitudinal multi-omics analysis of the gut-liver axis: Unraveling the molecular mechanisms of metabolic homeostasis regulation by Pd@Pt nanozymes

  2025cites this paper
• Roles of extracellular vesicles from different origins in metabolic-associated fatty liver disease: progress and perspectives

  2025cites this paper
• Palmitic acid induces macrophage sialylation via TLR4/MyD88/TRAF6/NF-κB signaling.

  2025cites this paper
• Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome

  2024cites this paper
• RG-I pectin-like polysaccharide from Rosa chinensis inhibits inflammation and fibrosis associated to HMGB1/TLR4/NF-κB signaling pathway to improve non-alcoholic steatohepatitis.

  2024cites this paper
• Identification of protein partners for small molecules reshapes the understanding of nonalcoholic steatohepatitis and drug discovery.

  2024cites this paper
• Hepatocyte-specific loss of DDB1 attenuates hepatic steatosis but aggravates liver inflammation and fibrosis in MASH

  2024cites this paper
• Role of pattern recognition receptors in the development of MASLD and potential therapeutic applications.

  2024cites this paper
• Imp7 siRNA nanoparticles protect against mechanical ventilation-associated liver injury by inhibiting HMGB1 production and NETs formation.

  2024cites this paper
• Inflammatory liver diseases and susceptibility to sepsis.

  2024cites this paper
• Vinpocetine and Lactobacillus improve fatty liver in rats: role of adiponectin and gut microbiome

  2024cites this paper
• Emerging Roles of High-mobility Group Box-1 in Liver Disease

  2024cites this paper
• Progressive dysfunction of the immune system as a factor preventing recoverable regeneration of the liver in chronic fibrosing diseases

  2023cites this paper
• Current insights into the interplay between gut microbiota-derived metabolites and metabolic-associated fatty liver disease

  2023cites this paper
• Biomarkers of liver diseases

  2023cites this paper
• Innate Immune System in the Pathogenesis of Non-Alcoholic Fatty Liver Disease

  2023cites this paper
• Vinpocetine and Lactobacillus improve fatty liver in rats via modulating the oxidative stress, inflammation, adiponectin and gut microbiome.

  2023cites this paper
• Insights into the role of vitamin D in targeting the culprits of non-alcoholic fatty liver disease.

  2023cites this paper
• Ubiquitination of cytoplasmic HMGB1 by RNF186 regulates hepatic lipophagy in non-alcoholic fatty liver disease.

  2023cites this paper
• Roles of immune dysregulation in MASLD.

  2023cites this paper
• Opportunities and considerations for studying liver disease with microphysiological systems on a chip.

  2023cites this paper
• Titanium dioxide nanoparticles: revealing the mechanisms underlying hepatotoxicity and effects in the gut microbiota

  2023cites this paper
• Maternal obstructive sleep apnea aggravates metabolic dysfunction-associated fatty liver disease via HMGB1-TLR4 signaling-mediated endoplasmic reticulum stress in male offspring rats.

  2023cites this paper
• Gamma-Muricholic Acid Inhibits Nonalcoholic Steatohepatitis: Abolishment of Steatosis-Dependent Peroxidative Impairment by FXR/SHP/LXRα/FASN Signaling

  2023cites this paper
• Gut-liver axis in the progression of nonalcoholic fatty liver disease: From the microbial derivatives-centered perspective.

  2023cites this paper
• Global trends and hotspots of treatment for nonalcoholic fatty liver disease: A bibliometric and visualization analysis (2010-2023)

  2023cites this paper
• Hepatic Macrophages as Targets for the MSC-Based Cell Therapy in Non-Alcoholic Steatohepatitis

  2023cites this paper
• New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk

  2023cites this paper
• Inducible nitric oxide synthase accelerates nonalcoholic fatty liver disease progression by regulating macrophage autophagy

  2023cites this paper
• Anti-Inflammatory and Therapeutic Effects of a Novel Small-Molecule Inhibitor of Inflammation in a Male C57BL/6J Mouse Model of Obesity-Induced NAFLD/MAFLD

  2023cites this paper
• Chlorogenic acid alleviated liver fibrosis in methionine and choline deficient diet-induced nonalcoholic steatohepatitis in mice and its mechanism.

  2022cites this paper
• The Potential Role of Gut Microbial-Derived Exosomes in Metabolic-Associated Fatty Liver Disease: Implications for Treatment

  2022cites this paper
• The contribution of sterile inflammation to the fatty liver disease and the potential therapies.

  2022cites this paper
• Intestinal Dysbiosis, the Tryptophan Pathway and Nonalcoholic Steatohepatitis

  2022cites this paper
• The role of the immune system in the pathogenesis of NAFLD and potential therapeutic impacts of mesenchymal stem cell-derived extracellular vesicles

  2022cites this paper
• Regulatory Networks, Management Approaches, and Emerging Treatments of Nonalcoholic Fatty Liver Disease

  2022cites this paper
• Enterobacter cloacae aggravates metabolic disease by inducing inflammation and lipid accumulation.

  2022cites this paper
• Hepatic macrophage mediated immune response in liver steatosis driven carcinogenesis

  2022cites this paper
• The role of oxidized lipid species in insulin resistance and NASH in children

  2022cites this paper
• Faecal microbiota transplantation is better than probiotics for tissue regeneration of type 2 diabetes mellitus injuries in mice

  2022cites this paper
• Mechanistic insights into the pleiotropic effects of butyrate as a potential therapeutic agent on NAFLD management: A systematic review

  2022cites this paper
• Targeting folliculin to selectively inhibit mTORC1: a promising strategy for treating nonalcoholic fatty liver disease

  2022cites this paper
• Activation of TAF9 via Danshensu-Induced Upregulation of HDAC1 Expression Alleviates Non-alcoholic Fatty Liver Disease

  2021cites this paper
• Identifying User Requirements for an Integrated E-Health Unit for Diabetes Mellitus

  2021cites this paper
• Role of modified diet and gut microbiota in metabolic endotoxemia in mice

  2021cites this paper
• The mechanism of increased intestinal palmitic acid absorption and its impact on hepatic stellate cell activation in nonalcoholic steatohepatitis

  2021cites this paper
• Influence of Diet and Levels of Zonulin, Lipopolysaccharide and C-Reactive Protein on Cardiometabolic Risk Factors in Young Subjects

  2021cites this paper
• SYK-3BP2 Pathway Activity in Parenchymal and Myeloid Cells Is a Key Pathogenic Factor in Metabolic Steatohepatitis

  2021cites this paper
• Attenuating Effects of Dieckol on High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease by Decreasing the NLRP3 Inflammasome and Pyroptosis

  2021cites this paper
• Recent Advances in Adipose Tissue Dysfunction and Its Role in the Pathogenesis of Non-Alcoholic Fatty Liver Disease

  2021cites this paper
• Nonalcoholic Fatty Liver Disease

  2021cites this paper
• Preventive and therapeutic role of betaine in liver disease: A review on molecular mechanisms.

  2021cites this paper
• Bile acid activated receptors: Integrating immune and metabolic regulation in non-alcoholic fatty liver disease

  2021cites this paper
• Circulatory Endothelin 1-Regulating RNAs Panel: Promising Biomarkers for Non-Invasive NAFLD/NASH Diagnosis and Stratification: Clinical and Molecular Pilot Study

  2021cites this paper
• Hepatic Macrophage as a Key Player in Fatty Liver Disease

  2021cites this paper
• Dipeptedyl peptidase-4 (DPP-4) inhibitor downregulates HMGB1/TLR4/NF-κB signaling pathway in a diabetic rat model of non-alcoholic fatty liver disease

  2021cites this paper
• The Role of Innate Immune Cells in Nonalcoholic Fatty Liver Disease

  2021cites this paper
• HMGB1: An overview of its roles in the pathogenesis of liver disease

  2021cites this paper
• Sparcl1 promotes nonalcoholic steatohepatitis progression in mice through upregulation of CCL2.

  2021cites this paper
• High mobility group box-1 promotes inflammation in endometriotic stromal cells through Toll-like receptor 4/nuclear factor-kappa B.

  2021cites this paper
• An RNA–RNA crosstalk network involving HMGB1 and RICTOR facilitates hepatocellular carcinoma tumorigenesis by promoting glutamine metabolism and impedes immunotherapy by PD-L1+ exosomes activity

  2021cites this paper
• Si-Wu-Tang Alleviates Nonalcoholic Fatty Liver Disease via Blocking TLR4-JNK and Caspase-8-GSDMD Signaling Pathways

  2020cites this paper
• Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma

  2020cites this paper
• Hepatic Macrophages in Liver Injury

  2020cites this paper
• The alteration of immune cells in the pathogenesis of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

  2020cites this paper
• Hepatocyte high-mobility group box 1 protects against steatosis and cellular stress during high fat diet feeding

  2020influential citation
• HMGB1 contributes to osteoarthritis of temporomandibular joint by inducing synovial angiogenesis.

  2020cites this paper
• Role of c-Jun N-terminal Kinase (JNK) in Obesity and Type 2 Diabetes

  2020cites this paper
• Pharmacological Effects of Salvianolic Acid B Against Oxidative Damage

  2020cites this paper
• Hepatoprotective Effect and Molecular Mechanisms of Hengshun Aromatic Vinegar on Non-Alcoholic Fatty Liver Disease

  2020cites this paper
• Crosstalk Between Liver Macrophages and Surrounding Cells in Nonalcoholic Steatohepatitis

  2020cites this paper
• Silencing of functional p53 attenuates NAFLD by promoting HMGB1-related autophagy induction

  2020cites this paper
• Extracellular gp96 is a crucial mediator for driving immune hyperactivation and liver damage

  2020cites this paper
• Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities

  2020cites this paper
• Sirtuin 3‐mediated deacetylation of acyl‐CoA synthetase family member 3 by protocatechuic acid attenuates non‐alcoholic fatty liver disease

  2020influential citation
• Magnesium isoglycyrrhizinate prevents the nonalcoholic hepatic steatosis via regulating energy homeostasis

  2020cites this paper
• Vitexin ameliorates chronic stress plub high fat diet-induced nonalcoholic fatty liver disease by inhibiting inflammation.

  2020cites this paper
• Downregulation of proinflammatory liver gene expression by Justicia spicigera and kaempferitrin in a murine model of obesity-induced by a high-fat diet

  2020cites this paper
• A new perspective of triptolide-associated hepatotoxicity: the relevance of NF-κB and NF-κB-mediated cellular FLICE-inhibitory protein

  2020cites this paper
• Increased risk of acute liver failure by pain killer drugs in NAFLD: Focus on nuclear receptors and their coactivators.

  2020cites this paper
• Arctigenin exhibits hepatoprotective activity in Toxoplasma gondii-infected host through HMGB1/TLR4/NF-κB pathway.

  2020cites this paper
• The liver as an endocrine organ - linking NAFLD and insulin resistance.

  2019cites this paper
• FBXW7 suppresses HMGB1-mediated innate immune signaling to attenuate hepatic inflammation and insulin resistance in a mouse model of nonalcoholic fatty liver disease

  2019cites this paper
• Melatonin safeguards against fatty liver by antagonizing TRAFs‐mediated ASK1 deubiquitination and stabilization in a β‐arrestin‐1 dependent manner

  2019cites this paper
• Hepatocellular iNOS protects liver from NASH through Nrf2-dependent activation of HO-1.

  2019cites this paper
• Plant Extracts and Reactive Oxygen Species as Two Counteracting Agents with Anti- and Pro-Obesity Properties

  2019cites this paper
• Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.

  2019cites this paper
• Role of macrophages in experimental liver injury and repair in mice.

  2019cites this paper
• Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response

  2019cites this paper
• The imbalance of peripheral interleukin‐18 and transforming growth factor‐&bgr;1 levels in patients with cirrhosis and esophageal varices

  2019cites this paper
• A Study of Macrophages in the Aging Liver and in the Host Response to Engineered Lung Scaffolds

  2019cites this paper
• Pathophysiological importance of bile cholesterol reabsorption: hepatic NPC1L1-exacerbated steatosis and decreasing VLDL-TG secretion in mice fed a high-fat diet

  2019cites this paper
• A global perspective on the crosstalk between saturated fatty acids and Toll-like receptor 4 in the etiology of inflammation and insulin resistance.

  2019cites this paper
• Mechanistic Studies of Cholesterol Lipotoxicity Pertinent to NASH

  2019influential citation
• Ablation of Hmgb1 in Intestinal Epithelial Cells Causes Intestinal Lipid Accumulation and Reduces NASH in Mice

  2019cites this paper